Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2008

View Archived Issues

Recent patents impart new anticancer agents

New therapeutic agents for iron-related disorders disclosed in recent Xenon patent

Recent Toray and Xenon patents disclose novel analgesic agents

PanGenetics to initiate phase I clinical trial of PG-102 in psoriatic arthritis

Galenea and Otsuka extend and expand schizophrenia research and development collaboration

Health Canada grants marketing authorization to Celgene's Revlimid for multiple myeloma

Cortex reports phase IIa results from CX717-RD-01 study in respiratory depression

Oncalis and ChemDiv sign exclusive license agreement for PI3K inhibitors

FDA accepts for review GTC Biotherapeutics' BLA for ATryn in deep vein thrombosis

Bavarian presents positive phase II data for Prostvac prostate cancer vaccine

Oral anticancer drug CP-4126 enters phase I clinical studies

Peregrine completes enrollment in first stage of phase II bavituximab trial

Pivotal phase III study shows MabThera delays disease progression in CLL

Update on Jak inhibitor INCB-18424 presented at International IRA Conference

XTL completes phase IIb bicifadine study for diabetic neuropathic pain

Single intravenous doses of BG-9928 increase urinary sodium excretion in heart failure patients

Mecasermin rinfabate raises IGF-I levels in preterm infants

Provectus provides update on phase II PV-10 study

FDA approves amendments to Oxford's phase III TRIST study of TroVax in renal cancer

Novo Nordisk and Innate enter agreements for rights to NN-1975/IPH-2101 and NN-8555/IPH-2301

R&D highlights from the UBS Global Life Sciences Conference in New York: Peptimmune

K-301 found safe and efficacious in scalp seborrheic dermatitis

Apogenix commences phase I with lead compound APG-101

Antisoma, ICR and CRT sign agreement for anticancer PPM1D inhibitors

Advances in the investigation of vandetanib for the treatment of cancer

Taisho discontinues development of TS-033

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...